Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [[maximum depth reached]]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/hepatitis-c-cure-may-cost-as-low-as-rs-67k-reema-nagarajan-4677900/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/hepatitis-c-cure-may-cost-as-low-as-rs-67k-reema-nagarajan-4677900/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [[maximum depth reached]]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/hepatitis-c-cure-may-cost-as-low-as-rs-67k-reema-nagarajan-4677900/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/hepatitis-c-cure-may-cost-as-low-as-rs-67k-reema-nagarajan-4677900/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff56f980dae-trace').style.display = (document.getElementById('cakeErr67ff56f980dae-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67ff56f980dae-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff56f980dae-code').style.display = (document.getElementById('cakeErr67ff56f980dae-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff56f980dae-context').style.display = (document.getElementById('cakeErr67ff56f980dae-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67ff56f980dae-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67ff56f980dae-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 29843,
		&#039;title&#039; =&gt; &#039;Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;NEW DELHI: &lt;/em&gt;In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease.&lt;br /&gt;
&lt;br /&gt;
The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction of the branded versions, into the Indian market within weeks. Some patients facing a threat to life currently import these drugs at a huge cost.&lt;br /&gt;
&lt;br /&gt;
According to the World Health Organisation, about 12 million people are infected with Hepatitis C in India. India is now one of the few countries where generics are available for interferon-free treatment. Pegylated interferon is an old, expensive, injectable chemotherapy drug with serious side effects used to treat Hep C in combination with sofosbuvir and ribavirin.&lt;br /&gt;
&lt;br /&gt;
The interferon-free treatment, which costs over $90,000 in the US and over 50,000 euros in the EU will be available to Indian patients for about Rs 55,000 or about $1,000 or even less thanks to competition between generic manufacturers.&lt;br /&gt;
&lt;br /&gt;
Indian generics are expected to revolutionise Hep C treatment in the region and all across the world as they did in the case of HIV/AIDS. People from countries where treatment is being rationed by the governments, such as in Australia, many European countries, the US, and Canada, already come to India to get treated and this trend is only likely to continue.&lt;br /&gt;
&lt;br /&gt;
Several patient groups, including International Treatment Preparedness Coalition - South Asia, the Delhi Network of Positive People, thalassemic patients&#039; groups and Medecins Sans Frontieres (MSF) or Doctors Without Borders have been petitioning the health ministry and the Drug Controller General of India (DCGI) seeking a clinical trial waiver for these drugs. Over a dozen patient groups and access-to-medicine activists from Indonesia, Thailand, Malaysia, Nepal and Vietnam too had sent similar appeals. &amp;quot;The requirement for a local clinical trial in India will delay the introduction of the new HCV drug daclatasvir in the country, and also in other high-burden countries in the region,&amp;quot; stated the appeals.&lt;br /&gt;
&lt;br /&gt;
HCV Patients with advanced liver disease, thalassemics, those with HIV co-infection or those with kidney disease undergoing dialysis who have hepatitis C need daclatasvir in combination with sofosbuvir for effective treatment. They cannot tolerate interferon and/or ribavirin and treatment with sofosbuvir alone was not possible for them. Hence they were left with no treatment option when the manufacturer of daclatasvir, Bristol Myers Squibbs (BMS), was not willing to bring the drug to India or other developing countries.&lt;br /&gt;
&lt;br /&gt;
Sofosbuvir was registered in India in January 2015 and daclatasvir was registered this month. The combo is seen as a very potent cure with about 90% cure rate and for no other disease has such a short-time cure become available, that too in a generic version.&lt;br /&gt;
&lt;br /&gt;
According to the recommendations of a high level committee, waiver of clinical trials in India for approval of a new drug that has already been approved outside India can be considered only in cases of national emergency, extreme urgency, and epidemic and for orphan drugs for rare diseases and drugs indicated for conditions/diseases for which there is no therapy. This was hampering the waiver that millions of Hep C patients were petitioning for.&lt;br /&gt;
&lt;br /&gt;
However, the technical committee, after examining the case of sofosbuvir, said that it was the only drug which could be safely used in several categories of Hepatitis C patients. In the case of daclatasvir, the committee said that the drug in combination with other medicinal products became imperative to expedite the treatment of all types (genotypes) of Hepatitis C and hence recommended the waiver.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;We welcome the availability of a pan-genotypic directly acting anti-viral (DAA) combination in India, which is a big step towards interferon free treatment for chronic HCV patients, many of whom urgently need treatment as they have advanced liver disease,&amp;quot; said Leena Menghaney, head of MSF&#039;s South Asia Access Campaign.&lt;br /&gt;
&lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 29 November, 2015, http://timesofindia.indiatimes.com/home/science/Hepatitis-C-cure-may-cost-as-low-as-Rs-67k/articleshow/49966218.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;hepatitis-c-cure-may-cost-as-low-as-rs-67k-reema-nagarajan-4677900&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4677900,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 29843,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Health,Access to Healthcare,generic medicines,Hepatitis C,Access to Medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India

NEW DELHI: In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;br /&gt;&lt;br /&gt;&lt;em&gt;NEW DELHI: &lt;/em&gt;In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease.&lt;br /&gt;&lt;br /&gt;The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction of the branded versions, into the Indian market within weeks. Some patients facing a threat to life currently import these drugs at a huge cost.&lt;br /&gt;&lt;br /&gt;According to the World Health Organisation, about 12 million people are infected with Hepatitis C in India. India is now one of the few countries where generics are available for interferon-free treatment. Pegylated interferon is an old, expensive, injectable chemotherapy drug with serious side effects used to treat Hep C in combination with sofosbuvir and ribavirin.&lt;br /&gt;&lt;br /&gt;The interferon-free treatment, which costs over $90,000 in the US and over 50,000 euros in the EU will be available to Indian patients for about Rs 55,000 or about $1,000 or even less thanks to competition between generic manufacturers.&lt;br /&gt;&lt;br /&gt;Indian generics are expected to revolutionise Hep C treatment in the region and all across the world as they did in the case of HIV/AIDS. People from countries where treatment is being rationed by the governments, such as in Australia, many European countries, the US, and Canada, already come to India to get treated and this trend is only likely to continue.&lt;br /&gt;&lt;br /&gt;Several patient groups, including International Treatment Preparedness Coalition - South Asia, the Delhi Network of Positive People, thalassemic patients&#039; groups and Medecins Sans Frontieres (MSF) or Doctors Without Borders have been petitioning the health ministry and the Drug Controller General of India (DCGI) seeking a clinical trial waiver for these drugs. Over a dozen patient groups and access-to-medicine activists from Indonesia, Thailand, Malaysia, Nepal and Vietnam too had sent similar appeals. &amp;quot;The requirement for a local clinical trial in India will delay the introduction of the new HCV drug daclatasvir in the country, and also in other high-burden countries in the region,&amp;quot; stated the appeals.&lt;br /&gt;&lt;br /&gt;HCV Patients with advanced liver disease, thalassemics, those with HIV co-infection or those with kidney disease undergoing dialysis who have hepatitis C need daclatasvir in combination with sofosbuvir for effective treatment. They cannot tolerate interferon and/or ribavirin and treatment with sofosbuvir alone was not possible for them. Hence they were left with no treatment option when the manufacturer of daclatasvir, Bristol Myers Squibbs (BMS), was not willing to bring the drug to India or other developing countries.&lt;br /&gt;&lt;br /&gt;Sofosbuvir was registered in India in January 2015 and daclatasvir was registered this month. The combo is seen as a very potent cure with about 90% cure rate and for no other disease has such a short-time cure become available, that too in a generic version.&lt;br /&gt;&lt;br /&gt;According to the recommendations of a high level committee, waiver of clinical trials in India for approval of a new drug that has already been approved outside India can be considered only in cases of national emergency, extreme urgency, and epidemic and for orphan drugs for rare diseases and drugs indicated for conditions/diseases for which there is no therapy. This was hampering the waiver that millions of Hep C patients were petitioning for.&lt;br /&gt;&lt;br /&gt;However, the technical committee, after examining the case of sofosbuvir, said that it was the only drug which could be safely used in several categories of Hepatitis C patients. In the case of daclatasvir, the committee said that the drug in combination with other medicinal products became imperative to expedite the treatment of all types (genotypes) of Hepatitis C and hence recommended the waiver.&lt;br /&gt;&lt;br /&gt;&amp;quot;We welcome the availability of a pan-genotypic directly acting anti-viral (DAA) combination in India, which is a big step towards interferon free treatment for chronic HCV patients, many of whom urgently need treatment as they have advanced liver disease,&amp;quot; said Leena Menghaney, head of MSF&#039;s South Asia Access Campaign.&lt;br /&gt;&lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 29843,
	&#039;title&#039; =&gt; &#039;Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;NEW DELHI: &lt;/em&gt;In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease.&lt;br /&gt;
&lt;br /&gt;
The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction of the branded versions, into the Indian market within weeks. Some patients facing a threat to life currently import these drugs at a huge cost.&lt;br /&gt;
&lt;br /&gt;
According to the World Health Organisation, about 12 million people are infected with Hepatitis C in India. India is now one of the few countries where generics are available for interferon-free treatment. Pegylated interferon is an old, expensive, injectable chemotherapy drug with serious side effects used to treat Hep C in combination with sofosbuvir and ribavirin.&lt;br /&gt;
&lt;br /&gt;
The interferon-free treatment, which costs over $90,000 in the US and over 50,000 euros in the EU will be available to Indian patients for about Rs 55,000 or about $1,000 or even less thanks to competition between generic manufacturers.&lt;br /&gt;
&lt;br /&gt;
Indian generics are expected to revolutionise Hep C treatment in the region and all across the world as they did in the case of HIV/AIDS. People from countries where treatment is being rationed by the governments, such as in Australia, many European countries, the US, and Canada, already come to India to get treated and this trend is only likely to continue.&lt;br /&gt;
&lt;br /&gt;
Several patient groups, including International Treatment Preparedness Coalition - South Asia, the Delhi Network of Positive People, thalassemic patients&#039; groups and Medecins Sans Frontieres (MSF) or Doctors Without Borders have been petitioning the health ministry and the Drug Controller General of India (DCGI) seeking a clinical trial waiver for these drugs. Over a dozen patient groups and access-to-medicine activists from Indonesia, Thailand, Malaysia, Nepal and Vietnam too had sent similar appeals. &amp;quot;The requirement for a local clinical trial in India will delay the introduction of the new HCV drug daclatasvir in the country, and also in other high-burden countries in the region,&amp;quot; stated the appeals.&lt;br /&gt;
&lt;br /&gt;
HCV Patients with advanced liver disease, thalassemics, those with HIV co-infection or those with kidney disease undergoing dialysis who have hepatitis C need daclatasvir in combination with sofosbuvir for effective treatment. They cannot tolerate interferon and/or ribavirin and treatment with sofosbuvir alone was not possible for them. Hence they were left with no treatment option when the manufacturer of daclatasvir, Bristol Myers Squibbs (BMS), was not willing to bring the drug to India or other developing countries.&lt;br /&gt;
&lt;br /&gt;
Sofosbuvir was registered in India in January 2015 and daclatasvir was registered this month. The combo is seen as a very potent cure with about 90% cure rate and for no other disease has such a short-time cure become available, that too in a generic version.&lt;br /&gt;
&lt;br /&gt;
According to the recommendations of a high level committee, waiver of clinical trials in India for approval of a new drug that has already been approved outside India can be considered only in cases of national emergency, extreme urgency, and epidemic and for orphan drugs for rare diseases and drugs indicated for conditions/diseases for which there is no therapy. This was hampering the waiver that millions of Hep C patients were petitioning for.&lt;br /&gt;
&lt;br /&gt;
However, the technical committee, after examining the case of sofosbuvir, said that it was the only drug which could be safely used in several categories of Hepatitis C patients. In the case of daclatasvir, the committee said that the drug in combination with other medicinal products became imperative to expedite the treatment of all types (genotypes) of Hepatitis C and hence recommended the waiver.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;We welcome the availability of a pan-genotypic directly acting anti-viral (DAA) combination in India, which is a big step towards interferon free treatment for chronic HCV patients, many of whom urgently need treatment as they have advanced liver disease,&amp;quot; said Leena Menghaney, head of MSF&#039;s South Asia Access Campaign.&lt;br /&gt;
&lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 29 November, 2015, http://timesofindia.indiatimes.com/home/science/Hepatitis-C-cure-may-cost-as-low-as-Rs-67k/articleshow/49966218.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;hepatitis-c-cure-may-cost-as-low-as-rs-67k-reema-nagarajan-4677900&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4677900,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 29843
$metaTitle = &#039;LATEST NEWS UPDATES | Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan&#039;
$metaKeywords = &#039;Access to Health,Access to Healthcare,generic medicines,Hepatitis C,Access to Medicines&#039;
$metaDesc = &#039;
-The Times of India

NEW DELHI: In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;br /&gt;&lt;br /&gt;&lt;em&gt;NEW DELHI: &lt;/em&gt;In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease.&lt;br /&gt;&lt;br /&gt;The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction of the branded versions, into the Indian market within weeks. Some patients facing a threat to life currently import these drugs at a huge cost.&lt;br /&gt;&lt;br /&gt;According to the World Health Organisation, about 12 million people are infected with Hepatitis C in India. India is now one of the few countries where generics are available for interferon-free treatment. Pegylated interferon is an old, expensive, injectable chemotherapy drug with serious side effects used to treat Hep C in combination with sofosbuvir and ribavirin.&lt;br /&gt;&lt;br /&gt;The interferon-free treatment, which costs over $90,000 in the US and over 50,000 euros in the EU will be available to Indian patients for about Rs 55,000 or about $1,000 or even less thanks to competition between generic manufacturers.&lt;br /&gt;&lt;br /&gt;Indian generics are expected to revolutionise Hep C treatment in the region and all across the world as they did in the case of HIV/AIDS. People from countries where treatment is being rationed by the governments, such as in Australia, many European countries, the US, and Canada, already come to India to get treated and this trend is only likely to continue.&lt;br /&gt;&lt;br /&gt;Several patient groups, including International Treatment Preparedness Coalition - South Asia, the Delhi Network of Positive People, thalassemic patients&#039; groups and Medecins Sans Frontieres (MSF) or Doctors Without Borders have been petitioning the health ministry and the Drug Controller General of India (DCGI) seeking a clinical trial waiver for these drugs. Over a dozen patient groups and access-to-medicine activists from Indonesia, Thailand, Malaysia, Nepal and Vietnam too had sent similar appeals. &amp;quot;The requirement for a local clinical trial in India will delay the introduction of the new HCV drug daclatasvir in the country, and also in other high-burden countries in the region,&amp;quot; stated the appeals.&lt;br /&gt;&lt;br /&gt;HCV Patients with advanced liver disease, thalassemics, those with HIV co-infection or those with kidney disease undergoing dialysis who have hepatitis C need daclatasvir in combination with sofosbuvir for effective treatment. They cannot tolerate interferon and/or ribavirin and treatment with sofosbuvir alone was not possible for them. Hence they were left with no treatment option when the manufacturer of daclatasvir, Bristol Myers Squibbs (BMS), was not willing to bring the drug to India or other developing countries.&lt;br /&gt;&lt;br /&gt;Sofosbuvir was registered in India in January 2015 and daclatasvir was registered this month. The combo is seen as a very potent cure with about 90% cure rate and for no other disease has such a short-time cure become available, that too in a generic version.&lt;br /&gt;&lt;br /&gt;According to the recommendations of a high level committee, waiver of clinical trials in India for approval of a new drug that has already been approved outside India can be considered only in cases of national emergency, extreme urgency, and epidemic and for orphan drugs for rare diseases and drugs indicated for conditions/diseases for which there is no therapy. This was hampering the waiver that millions of Hep C patients were petitioning for.&lt;br /&gt;&lt;br /&gt;However, the technical committee, after examining the case of sofosbuvir, said that it was the only drug which could be safely used in several categories of Hepatitis C patients. In the case of daclatasvir, the committee said that the drug in combination with other medicinal products became imperative to expedite the treatment of all types (genotypes) of Hepatitis C and hence recommended the waiver.&lt;br /&gt;&lt;br /&gt;&amp;quot;We welcome the availability of a pan-genotypic directly acting anti-viral (DAA) combination in India, which is a big step towards interferon free treatment for chronic HCV patients, many of whom urgently need treatment as they have advanced liver disease,&amp;quot; said Leena Menghaney, head of MSF&#039;s South Asia Access Campaign.&lt;br /&gt;&lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/hepatitis-c-cure-may-cost-as-low-as-rs-67k-reema-nagarajan-4677900.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan | Im4change.org</title>
    <meta name="description" content="
-The Times of India

NEW DELHI: In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India<br /><br /><em>NEW DELHI: </em>In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease.<br /><br />The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction of the branded versions, into the Indian market within weeks. Some patients facing a threat to life currently import these drugs at a huge cost.<br /><br />According to the World Health Organisation, about 12 million people are infected with Hepatitis C in India. India is now one of the few countries where generics are available for interferon-free treatment. Pegylated interferon is an old, expensive, injectable chemotherapy drug with serious side effects used to treat Hep C in combination with sofosbuvir and ribavirin.<br /><br />The interferon-free treatment, which costs over $90,000 in the US and over 50,000 euros in the EU will be available to Indian patients for about Rs 55,000 or about $1,000 or even less thanks to competition between generic manufacturers.<br /><br />Indian generics are expected to revolutionise Hep C treatment in the region and all across the world as they did in the case of HIV/AIDS. People from countries where treatment is being rationed by the governments, such as in Australia, many European countries, the US, and Canada, already come to India to get treated and this trend is only likely to continue.<br /><br />Several patient groups, including International Treatment Preparedness Coalition - South Asia, the Delhi Network of Positive People, thalassemic patients' groups and Medecins Sans Frontieres (MSF) or Doctors Without Borders have been petitioning the health ministry and the Drug Controller General of India (DCGI) seeking a clinical trial waiver for these drugs. Over a dozen patient groups and access-to-medicine activists from Indonesia, Thailand, Malaysia, Nepal and Vietnam too had sent similar appeals. &quot;The requirement for a local clinical trial in India will delay the introduction of the new HCV drug daclatasvir in the country, and also in other high-burden countries in the region,&quot; stated the appeals.<br /><br />HCV Patients with advanced liver disease, thalassemics, those with HIV co-infection or those with kidney disease undergoing dialysis who have hepatitis C need daclatasvir in combination with sofosbuvir for effective treatment. They cannot tolerate interferon and/or ribavirin and treatment with sofosbuvir alone was not possible for them. Hence they were left with no treatment option when the manufacturer of daclatasvir, Bristol Myers Squibbs (BMS), was not willing to bring the drug to India or other developing countries.<br /><br />Sofosbuvir was registered in India in January 2015 and daclatasvir was registered this month. The combo is seen as a very potent cure with about 90% cure rate and for no other disease has such a short-time cure become available, that too in a generic version.<br /><br />According to the recommendations of a high level committee, waiver of clinical trials in India for approval of a new drug that has already been approved outside India can be considered only in cases of national emergency, extreme urgency, and epidemic and for orphan drugs for rare diseases and drugs indicated for conditions/diseases for which there is no therapy. This was hampering the waiver that millions of Hep C patients were petitioning for.<br /><br />However, the technical committee, after examining the case of sofosbuvir, said that it was the only drug which could be safely used in several categories of Hepatitis C patients. In the case of daclatasvir, the committee said that the drug in combination with other medicinal products became imperative to expedite the treatment of all types (genotypes) of Hepatitis C and hence recommended the waiver.<br /><br />&quot;We welcome the availability of a pan-genotypic directly acting anti-viral (DAA) combination in India, which is a big step towards interferon free treatment for chronic HCV patients, many of whom urgently need treatment as they have advanced liver disease,&quot; said Leena Menghaney, head of MSF's South Asia Access Campaign.<br /><br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff56f980dae-trace').style.display = (document.getElementById('cakeErr67ff56f980dae-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67ff56f980dae-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff56f980dae-code').style.display = (document.getElementById('cakeErr67ff56f980dae-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff56f980dae-context').style.display = (document.getElementById('cakeErr67ff56f980dae-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67ff56f980dae-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67ff56f980dae-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 29843,
		&#039;title&#039; =&gt; &#039;Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;NEW DELHI: &lt;/em&gt;In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease.&lt;br /&gt;
&lt;br /&gt;
The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction of the branded versions, into the Indian market within weeks. Some patients facing a threat to life currently import these drugs at a huge cost.&lt;br /&gt;
&lt;br /&gt;
According to the World Health Organisation, about 12 million people are infected with Hepatitis C in India. India is now one of the few countries where generics are available for interferon-free treatment. Pegylated interferon is an old, expensive, injectable chemotherapy drug with serious side effects used to treat Hep C in combination with sofosbuvir and ribavirin.&lt;br /&gt;
&lt;br /&gt;
The interferon-free treatment, which costs over $90,000 in the US and over 50,000 euros in the EU will be available to Indian patients for about Rs 55,000 or about $1,000 or even less thanks to competition between generic manufacturers.&lt;br /&gt;
&lt;br /&gt;
Indian generics are expected to revolutionise Hep C treatment in the region and all across the world as they did in the case of HIV/AIDS. People from countries where treatment is being rationed by the governments, such as in Australia, many European countries, the US, and Canada, already come to India to get treated and this trend is only likely to continue.&lt;br /&gt;
&lt;br /&gt;
Several patient groups, including International Treatment Preparedness Coalition - South Asia, the Delhi Network of Positive People, thalassemic patients&#039; groups and Medecins Sans Frontieres (MSF) or Doctors Without Borders have been petitioning the health ministry and the Drug Controller General of India (DCGI) seeking a clinical trial waiver for these drugs. Over a dozen patient groups and access-to-medicine activists from Indonesia, Thailand, Malaysia, Nepal and Vietnam too had sent similar appeals. &amp;quot;The requirement for a local clinical trial in India will delay the introduction of the new HCV drug daclatasvir in the country, and also in other high-burden countries in the region,&amp;quot; stated the appeals.&lt;br /&gt;
&lt;br /&gt;
HCV Patients with advanced liver disease, thalassemics, those with HIV co-infection or those with kidney disease undergoing dialysis who have hepatitis C need daclatasvir in combination with sofosbuvir for effective treatment. They cannot tolerate interferon and/or ribavirin and treatment with sofosbuvir alone was not possible for them. Hence they were left with no treatment option when the manufacturer of daclatasvir, Bristol Myers Squibbs (BMS), was not willing to bring the drug to India or other developing countries.&lt;br /&gt;
&lt;br /&gt;
Sofosbuvir was registered in India in January 2015 and daclatasvir was registered this month. The combo is seen as a very potent cure with about 90% cure rate and for no other disease has such a short-time cure become available, that too in a generic version.&lt;br /&gt;
&lt;br /&gt;
According to the recommendations of a high level committee, waiver of clinical trials in India for approval of a new drug that has already been approved outside India can be considered only in cases of national emergency, extreme urgency, and epidemic and for orphan drugs for rare diseases and drugs indicated for conditions/diseases for which there is no therapy. This was hampering the waiver that millions of Hep C patients were petitioning for.&lt;br /&gt;
&lt;br /&gt;
However, the technical committee, after examining the case of sofosbuvir, said that it was the only drug which could be safely used in several categories of Hepatitis C patients. In the case of daclatasvir, the committee said that the drug in combination with other medicinal products became imperative to expedite the treatment of all types (genotypes) of Hepatitis C and hence recommended the waiver.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;We welcome the availability of a pan-genotypic directly acting anti-viral (DAA) combination in India, which is a big step towards interferon free treatment for chronic HCV patients, many of whom urgently need treatment as they have advanced liver disease,&amp;quot; said Leena Menghaney, head of MSF&#039;s South Asia Access Campaign.&lt;br /&gt;
&lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 29 November, 2015, http://timesofindia.indiatimes.com/home/science/Hepatitis-C-cure-may-cost-as-low-as-Rs-67k/articleshow/49966218.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;hepatitis-c-cure-may-cost-as-low-as-rs-67k-reema-nagarajan-4677900&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4677900,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 29843,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Health,Access to Healthcare,generic medicines,Hepatitis C,Access to Medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India

NEW DELHI: In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;br /&gt;&lt;br /&gt;&lt;em&gt;NEW DELHI: &lt;/em&gt;In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease.&lt;br /&gt;&lt;br /&gt;The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction of the branded versions, into the Indian market within weeks. Some patients facing a threat to life currently import these drugs at a huge cost.&lt;br /&gt;&lt;br /&gt;According to the World Health Organisation, about 12 million people are infected with Hepatitis C in India. India is now one of the few countries where generics are available for interferon-free treatment. Pegylated interferon is an old, expensive, injectable chemotherapy drug with serious side effects used to treat Hep C in combination with sofosbuvir and ribavirin.&lt;br /&gt;&lt;br /&gt;The interferon-free treatment, which costs over $90,000 in the US and over 50,000 euros in the EU will be available to Indian patients for about Rs 55,000 or about $1,000 or even less thanks to competition between generic manufacturers.&lt;br /&gt;&lt;br /&gt;Indian generics are expected to revolutionise Hep C treatment in the region and all across the world as they did in the case of HIV/AIDS. People from countries where treatment is being rationed by the governments, such as in Australia, many European countries, the US, and Canada, already come to India to get treated and this trend is only likely to continue.&lt;br /&gt;&lt;br /&gt;Several patient groups, including International Treatment Preparedness Coalition - South Asia, the Delhi Network of Positive People, thalassemic patients&#039; groups and Medecins Sans Frontieres (MSF) or Doctors Without Borders have been petitioning the health ministry and the Drug Controller General of India (DCGI) seeking a clinical trial waiver for these drugs. Over a dozen patient groups and access-to-medicine activists from Indonesia, Thailand, Malaysia, Nepal and Vietnam too had sent similar appeals. &amp;quot;The requirement for a local clinical trial in India will delay the introduction of the new HCV drug daclatasvir in the country, and also in other high-burden countries in the region,&amp;quot; stated the appeals.&lt;br /&gt;&lt;br /&gt;HCV Patients with advanced liver disease, thalassemics, those with HIV co-infection or those with kidney disease undergoing dialysis who have hepatitis C need daclatasvir in combination with sofosbuvir for effective treatment. They cannot tolerate interferon and/or ribavirin and treatment with sofosbuvir alone was not possible for them. Hence they were left with no treatment option when the manufacturer of daclatasvir, Bristol Myers Squibbs (BMS), was not willing to bring the drug to India or other developing countries.&lt;br /&gt;&lt;br /&gt;Sofosbuvir was registered in India in January 2015 and daclatasvir was registered this month. The combo is seen as a very potent cure with about 90% cure rate and for no other disease has such a short-time cure become available, that too in a generic version.&lt;br /&gt;&lt;br /&gt;According to the recommendations of a high level committee, waiver of clinical trials in India for approval of a new drug that has already been approved outside India can be considered only in cases of national emergency, extreme urgency, and epidemic and for orphan drugs for rare diseases and drugs indicated for conditions/diseases for which there is no therapy. This was hampering the waiver that millions of Hep C patients were petitioning for.&lt;br /&gt;&lt;br /&gt;However, the technical committee, after examining the case of sofosbuvir, said that it was the only drug which could be safely used in several categories of Hepatitis C patients. In the case of daclatasvir, the committee said that the drug in combination with other medicinal products became imperative to expedite the treatment of all types (genotypes) of Hepatitis C and hence recommended the waiver.&lt;br /&gt;&lt;br /&gt;&amp;quot;We welcome the availability of a pan-genotypic directly acting anti-viral (DAA) combination in India, which is a big step towards interferon free treatment for chronic HCV patients, many of whom urgently need treatment as they have advanced liver disease,&amp;quot; said Leena Menghaney, head of MSF&#039;s South Asia Access Campaign.&lt;br /&gt;&lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 29843,
	&#039;title&#039; =&gt; &#039;Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;NEW DELHI: &lt;/em&gt;In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease.&lt;br /&gt;
&lt;br /&gt;
The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction of the branded versions, into the Indian market within weeks. Some patients facing a threat to life currently import these drugs at a huge cost.&lt;br /&gt;
&lt;br /&gt;
According to the World Health Organisation, about 12 million people are infected with Hepatitis C in India. India is now one of the few countries where generics are available for interferon-free treatment. Pegylated interferon is an old, expensive, injectable chemotherapy drug with serious side effects used to treat Hep C in combination with sofosbuvir and ribavirin.&lt;br /&gt;
&lt;br /&gt;
The interferon-free treatment, which costs over $90,000 in the US and over 50,000 euros in the EU will be available to Indian patients for about Rs 55,000 or about $1,000 or even less thanks to competition between generic manufacturers.&lt;br /&gt;
&lt;br /&gt;
Indian generics are expected to revolutionise Hep C treatment in the region and all across the world as they did in the case of HIV/AIDS. People from countries where treatment is being rationed by the governments, such as in Australia, many European countries, the US, and Canada, already come to India to get treated and this trend is only likely to continue.&lt;br /&gt;
&lt;br /&gt;
Several patient groups, including International Treatment Preparedness Coalition - South Asia, the Delhi Network of Positive People, thalassemic patients&#039; groups and Medecins Sans Frontieres (MSF) or Doctors Without Borders have been petitioning the health ministry and the Drug Controller General of India (DCGI) seeking a clinical trial waiver for these drugs. Over a dozen patient groups and access-to-medicine activists from Indonesia, Thailand, Malaysia, Nepal and Vietnam too had sent similar appeals. &amp;quot;The requirement for a local clinical trial in India will delay the introduction of the new HCV drug daclatasvir in the country, and also in other high-burden countries in the region,&amp;quot; stated the appeals.&lt;br /&gt;
&lt;br /&gt;
HCV Patients with advanced liver disease, thalassemics, those with HIV co-infection or those with kidney disease undergoing dialysis who have hepatitis C need daclatasvir in combination with sofosbuvir for effective treatment. They cannot tolerate interferon and/or ribavirin and treatment with sofosbuvir alone was not possible for them. Hence they were left with no treatment option when the manufacturer of daclatasvir, Bristol Myers Squibbs (BMS), was not willing to bring the drug to India or other developing countries.&lt;br /&gt;
&lt;br /&gt;
Sofosbuvir was registered in India in January 2015 and daclatasvir was registered this month. The combo is seen as a very potent cure with about 90% cure rate and for no other disease has such a short-time cure become available, that too in a generic version.&lt;br /&gt;
&lt;br /&gt;
According to the recommendations of a high level committee, waiver of clinical trials in India for approval of a new drug that has already been approved outside India can be considered only in cases of national emergency, extreme urgency, and epidemic and for orphan drugs for rare diseases and drugs indicated for conditions/diseases for which there is no therapy. This was hampering the waiver that millions of Hep C patients were petitioning for.&lt;br /&gt;
&lt;br /&gt;
However, the technical committee, after examining the case of sofosbuvir, said that it was the only drug which could be safely used in several categories of Hepatitis C patients. In the case of daclatasvir, the committee said that the drug in combination with other medicinal products became imperative to expedite the treatment of all types (genotypes) of Hepatitis C and hence recommended the waiver.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;We welcome the availability of a pan-genotypic directly acting anti-viral (DAA) combination in India, which is a big step towards interferon free treatment for chronic HCV patients, many of whom urgently need treatment as they have advanced liver disease,&amp;quot; said Leena Menghaney, head of MSF&#039;s South Asia Access Campaign.&lt;br /&gt;
&lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 29 November, 2015, http://timesofindia.indiatimes.com/home/science/Hepatitis-C-cure-may-cost-as-low-as-Rs-67k/articleshow/49966218.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;hepatitis-c-cure-may-cost-as-low-as-rs-67k-reema-nagarajan-4677900&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4677900,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 29843
$metaTitle = &#039;LATEST NEWS UPDATES | Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan&#039;
$metaKeywords = &#039;Access to Health,Access to Healthcare,generic medicines,Hepatitis C,Access to Medicines&#039;
$metaDesc = &#039;
-The Times of India

NEW DELHI: In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;br /&gt;&lt;br /&gt;&lt;em&gt;NEW DELHI: &lt;/em&gt;In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease.&lt;br /&gt;&lt;br /&gt;The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction of the branded versions, into the Indian market within weeks. Some patients facing a threat to life currently import these drugs at a huge cost.&lt;br /&gt;&lt;br /&gt;According to the World Health Organisation, about 12 million people are infected with Hepatitis C in India. India is now one of the few countries where generics are available for interferon-free treatment. Pegylated interferon is an old, expensive, injectable chemotherapy drug with serious side effects used to treat Hep C in combination with sofosbuvir and ribavirin.&lt;br /&gt;&lt;br /&gt;The interferon-free treatment, which costs over $90,000 in the US and over 50,000 euros in the EU will be available to Indian patients for about Rs 55,000 or about $1,000 or even less thanks to competition between generic manufacturers.&lt;br /&gt;&lt;br /&gt;Indian generics are expected to revolutionise Hep C treatment in the region and all across the world as they did in the case of HIV/AIDS. People from countries where treatment is being rationed by the governments, such as in Australia, many European countries, the US, and Canada, already come to India to get treated and this trend is only likely to continue.&lt;br /&gt;&lt;br /&gt;Several patient groups, including International Treatment Preparedness Coalition - South Asia, the Delhi Network of Positive People, thalassemic patients&#039; groups and Medecins Sans Frontieres (MSF) or Doctors Without Borders have been petitioning the health ministry and the Drug Controller General of India (DCGI) seeking a clinical trial waiver for these drugs. Over a dozen patient groups and access-to-medicine activists from Indonesia, Thailand, Malaysia, Nepal and Vietnam too had sent similar appeals. &amp;quot;The requirement for a local clinical trial in India will delay the introduction of the new HCV drug daclatasvir in the country, and also in other high-burden countries in the region,&amp;quot; stated the appeals.&lt;br /&gt;&lt;br /&gt;HCV Patients with advanced liver disease, thalassemics, those with HIV co-infection or those with kidney disease undergoing dialysis who have hepatitis C need daclatasvir in combination with sofosbuvir for effective treatment. They cannot tolerate interferon and/or ribavirin and treatment with sofosbuvir alone was not possible for them. Hence they were left with no treatment option when the manufacturer of daclatasvir, Bristol Myers Squibbs (BMS), was not willing to bring the drug to India or other developing countries.&lt;br /&gt;&lt;br /&gt;Sofosbuvir was registered in India in January 2015 and daclatasvir was registered this month. The combo is seen as a very potent cure with about 90% cure rate and for no other disease has such a short-time cure become available, that too in a generic version.&lt;br /&gt;&lt;br /&gt;According to the recommendations of a high level committee, waiver of clinical trials in India for approval of a new drug that has already been approved outside India can be considered only in cases of national emergency, extreme urgency, and epidemic and for orphan drugs for rare diseases and drugs indicated for conditions/diseases for which there is no therapy. This was hampering the waiver that millions of Hep C patients were petitioning for.&lt;br /&gt;&lt;br /&gt;However, the technical committee, after examining the case of sofosbuvir, said that it was the only drug which could be safely used in several categories of Hepatitis C patients. In the case of daclatasvir, the committee said that the drug in combination with other medicinal products became imperative to expedite the treatment of all types (genotypes) of Hepatitis C and hence recommended the waiver.&lt;br /&gt;&lt;br /&gt;&amp;quot;We welcome the availability of a pan-genotypic directly acting anti-viral (DAA) combination in India, which is a big step towards interferon free treatment for chronic HCV patients, many of whom urgently need treatment as they have advanced liver disease,&amp;quot; said Leena Menghaney, head of MSF&#039;s South Asia Access Campaign.&lt;br /&gt;&lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/hepatitis-c-cure-may-cost-as-low-as-rs-67k-reema-nagarajan-4677900.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan | Im4change.org</title>
    <meta name="description" content="
-The Times of India

NEW DELHI: In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India<br /><br /><em>NEW DELHI: </em>In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease.<br /><br />The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction of the branded versions, into the Indian market within weeks. Some patients facing a threat to life currently import these drugs at a huge cost.<br /><br />According to the World Health Organisation, about 12 million people are infected with Hepatitis C in India. India is now one of the few countries where generics are available for interferon-free treatment. Pegylated interferon is an old, expensive, injectable chemotherapy drug with serious side effects used to treat Hep C in combination with sofosbuvir and ribavirin.<br /><br />The interferon-free treatment, which costs over $90,000 in the US and over 50,000 euros in the EU will be available to Indian patients for about Rs 55,000 or about $1,000 or even less thanks to competition between generic manufacturers.<br /><br />Indian generics are expected to revolutionise Hep C treatment in the region and all across the world as they did in the case of HIV/AIDS. People from countries where treatment is being rationed by the governments, such as in Australia, many European countries, the US, and Canada, already come to India to get treated and this trend is only likely to continue.<br /><br />Several patient groups, including International Treatment Preparedness Coalition - South Asia, the Delhi Network of Positive People, thalassemic patients' groups and Medecins Sans Frontieres (MSF) or Doctors Without Borders have been petitioning the health ministry and the Drug Controller General of India (DCGI) seeking a clinical trial waiver for these drugs. Over a dozen patient groups and access-to-medicine activists from Indonesia, Thailand, Malaysia, Nepal and Vietnam too had sent similar appeals. &quot;The requirement for a local clinical trial in India will delay the introduction of the new HCV drug daclatasvir in the country, and also in other high-burden countries in the region,&quot; stated the appeals.<br /><br />HCV Patients with advanced liver disease, thalassemics, those with HIV co-infection or those with kidney disease undergoing dialysis who have hepatitis C need daclatasvir in combination with sofosbuvir for effective treatment. They cannot tolerate interferon and/or ribavirin and treatment with sofosbuvir alone was not possible for them. Hence they were left with no treatment option when the manufacturer of daclatasvir, Bristol Myers Squibbs (BMS), was not willing to bring the drug to India or other developing countries.<br /><br />Sofosbuvir was registered in India in January 2015 and daclatasvir was registered this month. The combo is seen as a very potent cure with about 90% cure rate and for no other disease has such a short-time cure become available, that too in a generic version.<br /><br />According to the recommendations of a high level committee, waiver of clinical trials in India for approval of a new drug that has already been approved outside India can be considered only in cases of national emergency, extreme urgency, and epidemic and for orphan drugs for rare diseases and drugs indicated for conditions/diseases for which there is no therapy. This was hampering the waiver that millions of Hep C patients were petitioning for.<br /><br />However, the technical committee, after examining the case of sofosbuvir, said that it was the only drug which could be safely used in several categories of Hepatitis C patients. In the case of daclatasvir, the committee said that the drug in combination with other medicinal products became imperative to expedite the treatment of all types (genotypes) of Hepatitis C and hence recommended the waiver.<br /><br />&quot;We welcome the availability of a pan-genotypic directly acting anti-viral (DAA) combination in India, which is a big step towards interferon free treatment for chronic HCV patients, many of whom urgently need treatment as they have advanced liver disease,&quot; said Leena Menghaney, head of MSF's South Asia Access Campaign.<br /><br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff56f980dae-trace').style.display = (document.getElementById('cakeErr67ff56f980dae-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67ff56f980dae-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff56f980dae-code').style.display = (document.getElementById('cakeErr67ff56f980dae-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff56f980dae-context').style.display = (document.getElementById('cakeErr67ff56f980dae-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67ff56f980dae-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67ff56f980dae-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 29843,
		&#039;title&#039; =&gt; &#039;Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;NEW DELHI: &lt;/em&gt;In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease.&lt;br /&gt;
&lt;br /&gt;
The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction of the branded versions, into the Indian market within weeks. Some patients facing a threat to life currently import these drugs at a huge cost.&lt;br /&gt;
&lt;br /&gt;
According to the World Health Organisation, about 12 million people are infected with Hepatitis C in India. India is now one of the few countries where generics are available for interferon-free treatment. Pegylated interferon is an old, expensive, injectable chemotherapy drug with serious side effects used to treat Hep C in combination with sofosbuvir and ribavirin.&lt;br /&gt;
&lt;br /&gt;
The interferon-free treatment, which costs over $90,000 in the US and over 50,000 euros in the EU will be available to Indian patients for about Rs 55,000 or about $1,000 or even less thanks to competition between generic manufacturers.&lt;br /&gt;
&lt;br /&gt;
Indian generics are expected to revolutionise Hep C treatment in the region and all across the world as they did in the case of HIV/AIDS. People from countries where treatment is being rationed by the governments, such as in Australia, many European countries, the US, and Canada, already come to India to get treated and this trend is only likely to continue.&lt;br /&gt;
&lt;br /&gt;
Several patient groups, including International Treatment Preparedness Coalition - South Asia, the Delhi Network of Positive People, thalassemic patients&#039; groups and Medecins Sans Frontieres (MSF) or Doctors Without Borders have been petitioning the health ministry and the Drug Controller General of India (DCGI) seeking a clinical trial waiver for these drugs. Over a dozen patient groups and access-to-medicine activists from Indonesia, Thailand, Malaysia, Nepal and Vietnam too had sent similar appeals. &amp;quot;The requirement for a local clinical trial in India will delay the introduction of the new HCV drug daclatasvir in the country, and also in other high-burden countries in the region,&amp;quot; stated the appeals.&lt;br /&gt;
&lt;br /&gt;
HCV Patients with advanced liver disease, thalassemics, those with HIV co-infection or those with kidney disease undergoing dialysis who have hepatitis C need daclatasvir in combination with sofosbuvir for effective treatment. They cannot tolerate interferon and/or ribavirin and treatment with sofosbuvir alone was not possible for them. Hence they were left with no treatment option when the manufacturer of daclatasvir, Bristol Myers Squibbs (BMS), was not willing to bring the drug to India or other developing countries.&lt;br /&gt;
&lt;br /&gt;
Sofosbuvir was registered in India in January 2015 and daclatasvir was registered this month. The combo is seen as a very potent cure with about 90% cure rate and for no other disease has such a short-time cure become available, that too in a generic version.&lt;br /&gt;
&lt;br /&gt;
According to the recommendations of a high level committee, waiver of clinical trials in India for approval of a new drug that has already been approved outside India can be considered only in cases of national emergency, extreme urgency, and epidemic and for orphan drugs for rare diseases and drugs indicated for conditions/diseases for which there is no therapy. This was hampering the waiver that millions of Hep C patients were petitioning for.&lt;br /&gt;
&lt;br /&gt;
However, the technical committee, after examining the case of sofosbuvir, said that it was the only drug which could be safely used in several categories of Hepatitis C patients. In the case of daclatasvir, the committee said that the drug in combination with other medicinal products became imperative to expedite the treatment of all types (genotypes) of Hepatitis C and hence recommended the waiver.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;We welcome the availability of a pan-genotypic directly acting anti-viral (DAA) combination in India, which is a big step towards interferon free treatment for chronic HCV patients, many of whom urgently need treatment as they have advanced liver disease,&amp;quot; said Leena Menghaney, head of MSF&#039;s South Asia Access Campaign.&lt;br /&gt;
&lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 29 November, 2015, http://timesofindia.indiatimes.com/home/science/Hepatitis-C-cure-may-cost-as-low-as-Rs-67k/articleshow/49966218.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;hepatitis-c-cure-may-cost-as-low-as-rs-67k-reema-nagarajan-4677900&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4677900,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 29843,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Health,Access to Healthcare,generic medicines,Hepatitis C,Access to Medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India

NEW DELHI: In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;br /&gt;&lt;br /&gt;&lt;em&gt;NEW DELHI: &lt;/em&gt;In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease.&lt;br /&gt;&lt;br /&gt;The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction of the branded versions, into the Indian market within weeks. Some patients facing a threat to life currently import these drugs at a huge cost.&lt;br /&gt;&lt;br /&gt;According to the World Health Organisation, about 12 million people are infected with Hepatitis C in India. India is now one of the few countries where generics are available for interferon-free treatment. Pegylated interferon is an old, expensive, injectable chemotherapy drug with serious side effects used to treat Hep C in combination with sofosbuvir and ribavirin.&lt;br /&gt;&lt;br /&gt;The interferon-free treatment, which costs over $90,000 in the US and over 50,000 euros in the EU will be available to Indian patients for about Rs 55,000 or about $1,000 or even less thanks to competition between generic manufacturers.&lt;br /&gt;&lt;br /&gt;Indian generics are expected to revolutionise Hep C treatment in the region and all across the world as they did in the case of HIV/AIDS. People from countries where treatment is being rationed by the governments, such as in Australia, many European countries, the US, and Canada, already come to India to get treated and this trend is only likely to continue.&lt;br /&gt;&lt;br /&gt;Several patient groups, including International Treatment Preparedness Coalition - South Asia, the Delhi Network of Positive People, thalassemic patients&#039; groups and Medecins Sans Frontieres (MSF) or Doctors Without Borders have been petitioning the health ministry and the Drug Controller General of India (DCGI) seeking a clinical trial waiver for these drugs. Over a dozen patient groups and access-to-medicine activists from Indonesia, Thailand, Malaysia, Nepal and Vietnam too had sent similar appeals. &amp;quot;The requirement for a local clinical trial in India will delay the introduction of the new HCV drug daclatasvir in the country, and also in other high-burden countries in the region,&amp;quot; stated the appeals.&lt;br /&gt;&lt;br /&gt;HCV Patients with advanced liver disease, thalassemics, those with HIV co-infection or those with kidney disease undergoing dialysis who have hepatitis C need daclatasvir in combination with sofosbuvir for effective treatment. They cannot tolerate interferon and/or ribavirin and treatment with sofosbuvir alone was not possible for them. Hence they were left with no treatment option when the manufacturer of daclatasvir, Bristol Myers Squibbs (BMS), was not willing to bring the drug to India or other developing countries.&lt;br /&gt;&lt;br /&gt;Sofosbuvir was registered in India in January 2015 and daclatasvir was registered this month. The combo is seen as a very potent cure with about 90% cure rate and for no other disease has such a short-time cure become available, that too in a generic version.&lt;br /&gt;&lt;br /&gt;According to the recommendations of a high level committee, waiver of clinical trials in India for approval of a new drug that has already been approved outside India can be considered only in cases of national emergency, extreme urgency, and epidemic and for orphan drugs for rare diseases and drugs indicated for conditions/diseases for which there is no therapy. This was hampering the waiver that millions of Hep C patients were petitioning for.&lt;br /&gt;&lt;br /&gt;However, the technical committee, after examining the case of sofosbuvir, said that it was the only drug which could be safely used in several categories of Hepatitis C patients. In the case of daclatasvir, the committee said that the drug in combination with other medicinal products became imperative to expedite the treatment of all types (genotypes) of Hepatitis C and hence recommended the waiver.&lt;br /&gt;&lt;br /&gt;&amp;quot;We welcome the availability of a pan-genotypic directly acting anti-viral (DAA) combination in India, which is a big step towards interferon free treatment for chronic HCV patients, many of whom urgently need treatment as they have advanced liver disease,&amp;quot; said Leena Menghaney, head of MSF&#039;s South Asia Access Campaign.&lt;br /&gt;&lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 29843,
	&#039;title&#039; =&gt; &#039;Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;NEW DELHI: &lt;/em&gt;In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease.&lt;br /&gt;
&lt;br /&gt;
The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction of the branded versions, into the Indian market within weeks. Some patients facing a threat to life currently import these drugs at a huge cost.&lt;br /&gt;
&lt;br /&gt;
According to the World Health Organisation, about 12 million people are infected with Hepatitis C in India. India is now one of the few countries where generics are available for interferon-free treatment. Pegylated interferon is an old, expensive, injectable chemotherapy drug with serious side effects used to treat Hep C in combination with sofosbuvir and ribavirin.&lt;br /&gt;
&lt;br /&gt;
The interferon-free treatment, which costs over $90,000 in the US and over 50,000 euros in the EU will be available to Indian patients for about Rs 55,000 or about $1,000 or even less thanks to competition between generic manufacturers.&lt;br /&gt;
&lt;br /&gt;
Indian generics are expected to revolutionise Hep C treatment in the region and all across the world as they did in the case of HIV/AIDS. People from countries where treatment is being rationed by the governments, such as in Australia, many European countries, the US, and Canada, already come to India to get treated and this trend is only likely to continue.&lt;br /&gt;
&lt;br /&gt;
Several patient groups, including International Treatment Preparedness Coalition - South Asia, the Delhi Network of Positive People, thalassemic patients&#039; groups and Medecins Sans Frontieres (MSF) or Doctors Without Borders have been petitioning the health ministry and the Drug Controller General of India (DCGI) seeking a clinical trial waiver for these drugs. Over a dozen patient groups and access-to-medicine activists from Indonesia, Thailand, Malaysia, Nepal and Vietnam too had sent similar appeals. &amp;quot;The requirement for a local clinical trial in India will delay the introduction of the new HCV drug daclatasvir in the country, and also in other high-burden countries in the region,&amp;quot; stated the appeals.&lt;br /&gt;
&lt;br /&gt;
HCV Patients with advanced liver disease, thalassemics, those with HIV co-infection or those with kidney disease undergoing dialysis who have hepatitis C need daclatasvir in combination with sofosbuvir for effective treatment. They cannot tolerate interferon and/or ribavirin and treatment with sofosbuvir alone was not possible for them. Hence they were left with no treatment option when the manufacturer of daclatasvir, Bristol Myers Squibbs (BMS), was not willing to bring the drug to India or other developing countries.&lt;br /&gt;
&lt;br /&gt;
Sofosbuvir was registered in India in January 2015 and daclatasvir was registered this month. The combo is seen as a very potent cure with about 90% cure rate and for no other disease has such a short-time cure become available, that too in a generic version.&lt;br /&gt;
&lt;br /&gt;
According to the recommendations of a high level committee, waiver of clinical trials in India for approval of a new drug that has already been approved outside India can be considered only in cases of national emergency, extreme urgency, and epidemic and for orphan drugs for rare diseases and drugs indicated for conditions/diseases for which there is no therapy. This was hampering the waiver that millions of Hep C patients were petitioning for.&lt;br /&gt;
&lt;br /&gt;
However, the technical committee, after examining the case of sofosbuvir, said that it was the only drug which could be safely used in several categories of Hepatitis C patients. In the case of daclatasvir, the committee said that the drug in combination with other medicinal products became imperative to expedite the treatment of all types (genotypes) of Hepatitis C and hence recommended the waiver.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;We welcome the availability of a pan-genotypic directly acting anti-viral (DAA) combination in India, which is a big step towards interferon free treatment for chronic HCV patients, many of whom urgently need treatment as they have advanced liver disease,&amp;quot; said Leena Menghaney, head of MSF&#039;s South Asia Access Campaign.&lt;br /&gt;
&lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 29 November, 2015, http://timesofindia.indiatimes.com/home/science/Hepatitis-C-cure-may-cost-as-low-as-Rs-67k/articleshow/49966218.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;hepatitis-c-cure-may-cost-as-low-as-rs-67k-reema-nagarajan-4677900&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4677900,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 29843
$metaTitle = &#039;LATEST NEWS UPDATES | Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan&#039;
$metaKeywords = &#039;Access to Health,Access to Healthcare,generic medicines,Hepatitis C,Access to Medicines&#039;
$metaDesc = &#039;
-The Times of India

NEW DELHI: In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;br /&gt;&lt;br /&gt;&lt;em&gt;NEW DELHI: &lt;/em&gt;In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease.&lt;br /&gt;&lt;br /&gt;The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction of the branded versions, into the Indian market within weeks. Some patients facing a threat to life currently import these drugs at a huge cost.&lt;br /&gt;&lt;br /&gt;According to the World Health Organisation, about 12 million people are infected with Hepatitis C in India. India is now one of the few countries where generics are available for interferon-free treatment. Pegylated interferon is an old, expensive, injectable chemotherapy drug with serious side effects used to treat Hep C in combination with sofosbuvir and ribavirin.&lt;br /&gt;&lt;br /&gt;The interferon-free treatment, which costs over $90,000 in the US and over 50,000 euros in the EU will be available to Indian patients for about Rs 55,000 or about $1,000 or even less thanks to competition between generic manufacturers.&lt;br /&gt;&lt;br /&gt;Indian generics are expected to revolutionise Hep C treatment in the region and all across the world as they did in the case of HIV/AIDS. People from countries where treatment is being rationed by the governments, such as in Australia, many European countries, the US, and Canada, already come to India to get treated and this trend is only likely to continue.&lt;br /&gt;&lt;br /&gt;Several patient groups, including International Treatment Preparedness Coalition - South Asia, the Delhi Network of Positive People, thalassemic patients&#039; groups and Medecins Sans Frontieres (MSF) or Doctors Without Borders have been petitioning the health ministry and the Drug Controller General of India (DCGI) seeking a clinical trial waiver for these drugs. Over a dozen patient groups and access-to-medicine activists from Indonesia, Thailand, Malaysia, Nepal and Vietnam too had sent similar appeals. &amp;quot;The requirement for a local clinical trial in India will delay the introduction of the new HCV drug daclatasvir in the country, and also in other high-burden countries in the region,&amp;quot; stated the appeals.&lt;br /&gt;&lt;br /&gt;HCV Patients with advanced liver disease, thalassemics, those with HIV co-infection or those with kidney disease undergoing dialysis who have hepatitis C need daclatasvir in combination with sofosbuvir for effective treatment. They cannot tolerate interferon and/or ribavirin and treatment with sofosbuvir alone was not possible for them. Hence they were left with no treatment option when the manufacturer of daclatasvir, Bristol Myers Squibbs (BMS), was not willing to bring the drug to India or other developing countries.&lt;br /&gt;&lt;br /&gt;Sofosbuvir was registered in India in January 2015 and daclatasvir was registered this month. The combo is seen as a very potent cure with about 90% cure rate and for no other disease has such a short-time cure become available, that too in a generic version.&lt;br /&gt;&lt;br /&gt;According to the recommendations of a high level committee, waiver of clinical trials in India for approval of a new drug that has already been approved outside India can be considered only in cases of national emergency, extreme urgency, and epidemic and for orphan drugs for rare diseases and drugs indicated for conditions/diseases for which there is no therapy. This was hampering the waiver that millions of Hep C patients were petitioning for.&lt;br /&gt;&lt;br /&gt;However, the technical committee, after examining the case of sofosbuvir, said that it was the only drug which could be safely used in several categories of Hepatitis C patients. In the case of daclatasvir, the committee said that the drug in combination with other medicinal products became imperative to expedite the treatment of all types (genotypes) of Hepatitis C and hence recommended the waiver.&lt;br /&gt;&lt;br /&gt;&amp;quot;We welcome the availability of a pan-genotypic directly acting anti-viral (DAA) combination in India, which is a big step towards interferon free treatment for chronic HCV patients, many of whom urgently need treatment as they have advanced liver disease,&amp;quot; said Leena Menghaney, head of MSF&#039;s South Asia Access Campaign.&lt;br /&gt;&lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/hepatitis-c-cure-may-cost-as-low-as-rs-67k-reema-nagarajan-4677900.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan | Im4change.org</title>
    <meta name="description" content="
-The Times of India

NEW DELHI: In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India<br /><br /><em>NEW DELHI: </em>In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease.<br /><br />The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction of the branded versions, into the Indian market within weeks. Some patients facing a threat to life currently import these drugs at a huge cost.<br /><br />According to the World Health Organisation, about 12 million people are infected with Hepatitis C in India. India is now one of the few countries where generics are available for interferon-free treatment. Pegylated interferon is an old, expensive, injectable chemotherapy drug with serious side effects used to treat Hep C in combination with sofosbuvir and ribavirin.<br /><br />The interferon-free treatment, which costs over $90,000 in the US and over 50,000 euros in the EU will be available to Indian patients for about Rs 55,000 or about $1,000 or even less thanks to competition between generic manufacturers.<br /><br />Indian generics are expected to revolutionise Hep C treatment in the region and all across the world as they did in the case of HIV/AIDS. People from countries where treatment is being rationed by the governments, such as in Australia, many European countries, the US, and Canada, already come to India to get treated and this trend is only likely to continue.<br /><br />Several patient groups, including International Treatment Preparedness Coalition - South Asia, the Delhi Network of Positive People, thalassemic patients' groups and Medecins Sans Frontieres (MSF) or Doctors Without Borders have been petitioning the health ministry and the Drug Controller General of India (DCGI) seeking a clinical trial waiver for these drugs. Over a dozen patient groups and access-to-medicine activists from Indonesia, Thailand, Malaysia, Nepal and Vietnam too had sent similar appeals. &quot;The requirement for a local clinical trial in India will delay the introduction of the new HCV drug daclatasvir in the country, and also in other high-burden countries in the region,&quot; stated the appeals.<br /><br />HCV Patients with advanced liver disease, thalassemics, those with HIV co-infection or those with kidney disease undergoing dialysis who have hepatitis C need daclatasvir in combination with sofosbuvir for effective treatment. They cannot tolerate interferon and/or ribavirin and treatment with sofosbuvir alone was not possible for them. Hence they were left with no treatment option when the manufacturer of daclatasvir, Bristol Myers Squibbs (BMS), was not willing to bring the drug to India or other developing countries.<br /><br />Sofosbuvir was registered in India in January 2015 and daclatasvir was registered this month. The combo is seen as a very potent cure with about 90% cure rate and for no other disease has such a short-time cure become available, that too in a generic version.<br /><br />According to the recommendations of a high level committee, waiver of clinical trials in India for approval of a new drug that has already been approved outside India can be considered only in cases of national emergency, extreme urgency, and epidemic and for orphan drugs for rare diseases and drugs indicated for conditions/diseases for which there is no therapy. This was hampering the waiver that millions of Hep C patients were petitioning for.<br /><br />However, the technical committee, after examining the case of sofosbuvir, said that it was the only drug which could be safely used in several categories of Hepatitis C patients. In the case of daclatasvir, the committee said that the drug in combination with other medicinal products became imperative to expedite the treatment of all types (genotypes) of Hepatitis C and hence recommended the waiver.<br /><br />&quot;We welcome the availability of a pan-genotypic directly acting anti-viral (DAA) combination in India, which is a big step towards interferon free treatment for chronic HCV patients, many of whom urgently need treatment as they have advanced liver disease,&quot; said Leena Menghaney, head of MSF's South Asia Access Campaign.<br /><br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 29843,
		'title' => 'Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan',
		'subheading' => '',
		'description' => '<div align="justify">
-The Times of India<br />
<br />
<em>NEW DELHI: </em>In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease.<br />
<br />
The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction of the branded versions, into the Indian market within weeks. Some patients facing a threat to life currently import these drugs at a huge cost.<br />
<br />
According to the World Health Organisation, about 12 million people are infected with Hepatitis C in India. India is now one of the few countries where generics are available for interferon-free treatment. Pegylated interferon is an old, expensive, injectable chemotherapy drug with serious side effects used to treat Hep C in combination with sofosbuvir and ribavirin.<br />
<br />
The interferon-free treatment, which costs over $90,000 in the US and over 50,000 euros in the EU will be available to Indian patients for about Rs 55,000 or about $1,000 or even less thanks to competition between generic manufacturers.<br />
<br />
Indian generics are expected to revolutionise Hep C treatment in the region and all across the world as they did in the case of HIV/AIDS. People from countries where treatment is being rationed by the governments, such as in Australia, many European countries, the US, and Canada, already come to India to get treated and this trend is only likely to continue.<br />
<br />
Several patient groups, including International Treatment Preparedness Coalition - South Asia, the Delhi Network of Positive People, thalassemic patients' groups and Medecins Sans Frontieres (MSF) or Doctors Without Borders have been petitioning the health ministry and the Drug Controller General of India (DCGI) seeking a clinical trial waiver for these drugs. Over a dozen patient groups and access-to-medicine activists from Indonesia, Thailand, Malaysia, Nepal and Vietnam too had sent similar appeals. &quot;The requirement for a local clinical trial in India will delay the introduction of the new HCV drug daclatasvir in the country, and also in other high-burden countries in the region,&quot; stated the appeals.<br />
<br />
HCV Patients with advanced liver disease, thalassemics, those with HIV co-infection or those with kidney disease undergoing dialysis who have hepatitis C need daclatasvir in combination with sofosbuvir for effective treatment. They cannot tolerate interferon and/or ribavirin and treatment with sofosbuvir alone was not possible for them. Hence they were left with no treatment option when the manufacturer of daclatasvir, Bristol Myers Squibbs (BMS), was not willing to bring the drug to India or other developing countries.<br />
<br />
Sofosbuvir was registered in India in January 2015 and daclatasvir was registered this month. The combo is seen as a very potent cure with about 90% cure rate and for no other disease has such a short-time cure become available, that too in a generic version.<br />
<br />
According to the recommendations of a high level committee, waiver of clinical trials in India for approval of a new drug that has already been approved outside India can be considered only in cases of national emergency, extreme urgency, and epidemic and for orphan drugs for rare diseases and drugs indicated for conditions/diseases for which there is no therapy. This was hampering the waiver that millions of Hep C patients were petitioning for.<br />
<br />
However, the technical committee, after examining the case of sofosbuvir, said that it was the only drug which could be safely used in several categories of Hepatitis C patients. In the case of daclatasvir, the committee said that the drug in combination with other medicinal products became imperative to expedite the treatment of all types (genotypes) of Hepatitis C and hence recommended the waiver.<br />
<br />
&quot;We welcome the availability of a pan-genotypic directly acting anti-viral (DAA) combination in India, which is a big step towards interferon free treatment for chronic HCV patients, many of whom urgently need treatment as they have advanced liver disease,&quot; said Leena Menghaney, head of MSF's South Asia Access Campaign.<br />
<br />
</div>',
		'credit_writer' => 'The Times of India, 29 November, 2015, http://timesofindia.indiatimes.com/home/science/Hepatitis-C-cure-may-cost-as-low-as-Rs-67k/articleshow/49966218.cms',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'hepatitis-c-cure-may-cost-as-low-as-rs-67k-reema-nagarajan-4677900',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 4677900,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 29843,
	'metaTitle' => 'LATEST NEWS UPDATES | Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan',
	'metaKeywords' => 'Access to Health,Access to Healthcare,generic medicines,Hepatitis C,Access to Medicines',
	'metaDesc' => '
-The Times of India

NEW DELHI: In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial...',
	'disp' => '<div align="justify">-The Times of India<br /><br /><em>NEW DELHI: </em>In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease.<br /><br />The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction of the branded versions, into the Indian market within weeks. Some patients facing a threat to life currently import these drugs at a huge cost.<br /><br />According to the World Health Organisation, about 12 million people are infected with Hepatitis C in India. India is now one of the few countries where generics are available for interferon-free treatment. Pegylated interferon is an old, expensive, injectable chemotherapy drug with serious side effects used to treat Hep C in combination with sofosbuvir and ribavirin.<br /><br />The interferon-free treatment, which costs over $90,000 in the US and over 50,000 euros in the EU will be available to Indian patients for about Rs 55,000 or about $1,000 or even less thanks to competition between generic manufacturers.<br /><br />Indian generics are expected to revolutionise Hep C treatment in the region and all across the world as they did in the case of HIV/AIDS. People from countries where treatment is being rationed by the governments, such as in Australia, many European countries, the US, and Canada, already come to India to get treated and this trend is only likely to continue.<br /><br />Several patient groups, including International Treatment Preparedness Coalition - South Asia, the Delhi Network of Positive People, thalassemic patients' groups and Medecins Sans Frontieres (MSF) or Doctors Without Borders have been petitioning the health ministry and the Drug Controller General of India (DCGI) seeking a clinical trial waiver for these drugs. Over a dozen patient groups and access-to-medicine activists from Indonesia, Thailand, Malaysia, Nepal and Vietnam too had sent similar appeals. &quot;The requirement for a local clinical trial in India will delay the introduction of the new HCV drug daclatasvir in the country, and also in other high-burden countries in the region,&quot; stated the appeals.<br /><br />HCV Patients with advanced liver disease, thalassemics, those with HIV co-infection or those with kidney disease undergoing dialysis who have hepatitis C need daclatasvir in combination with sofosbuvir for effective treatment. They cannot tolerate interferon and/or ribavirin and treatment with sofosbuvir alone was not possible for them. Hence they were left with no treatment option when the manufacturer of daclatasvir, Bristol Myers Squibbs (BMS), was not willing to bring the drug to India or other developing countries.<br /><br />Sofosbuvir was registered in India in January 2015 and daclatasvir was registered this month. The combo is seen as a very potent cure with about 90% cure rate and for no other disease has such a short-time cure become available, that too in a generic version.<br /><br />According to the recommendations of a high level committee, waiver of clinical trials in India for approval of a new drug that has already been approved outside India can be considered only in cases of national emergency, extreme urgency, and epidemic and for orphan drugs for rare diseases and drugs indicated for conditions/diseases for which there is no therapy. This was hampering the waiver that millions of Hep C patients were petitioning for.<br /><br />However, the technical committee, after examining the case of sofosbuvir, said that it was the only drug which could be safely used in several categories of Hepatitis C patients. In the case of daclatasvir, the committee said that the drug in combination with other medicinal products became imperative to expedite the treatment of all types (genotypes) of Hepatitis C and hence recommended the waiver.<br /><br />&quot;We welcome the availability of a pan-genotypic directly acting anti-viral (DAA) combination in India, which is a big step towards interferon free treatment for chronic HCV patients, many of whom urgently need treatment as they have advanced liver disease,&quot; said Leena Menghaney, head of MSF's South Asia Access Campaign.<br /><br /></div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 29843,
	'title' => 'Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan',
	'subheading' => '',
	'description' => '<div align="justify">
-The Times of India<br />
<br />
<em>NEW DELHI: </em>In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease.<br />
<br />
The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction of the branded versions, into the Indian market within weeks. Some patients facing a threat to life currently import these drugs at a huge cost.<br />
<br />
According to the World Health Organisation, about 12 million people are infected with Hepatitis C in India. India is now one of the few countries where generics are available for interferon-free treatment. Pegylated interferon is an old, expensive, injectable chemotherapy drug with serious side effects used to treat Hep C in combination with sofosbuvir and ribavirin.<br />
<br />
The interferon-free treatment, which costs over $90,000 in the US and over 50,000 euros in the EU will be available to Indian patients for about Rs 55,000 or about $1,000 or even less thanks to competition between generic manufacturers.<br />
<br />
Indian generics are expected to revolutionise Hep C treatment in the region and all across the world as they did in the case of HIV/AIDS. People from countries where treatment is being rationed by the governments, such as in Australia, many European countries, the US, and Canada, already come to India to get treated and this trend is only likely to continue.<br />
<br />
Several patient groups, including International Treatment Preparedness Coalition - South Asia, the Delhi Network of Positive People, thalassemic patients' groups and Medecins Sans Frontieres (MSF) or Doctors Without Borders have been petitioning the health ministry and the Drug Controller General of India (DCGI) seeking a clinical trial waiver for these drugs. Over a dozen patient groups and access-to-medicine activists from Indonesia, Thailand, Malaysia, Nepal and Vietnam too had sent similar appeals. &quot;The requirement for a local clinical trial in India will delay the introduction of the new HCV drug daclatasvir in the country, and also in other high-burden countries in the region,&quot; stated the appeals.<br />
<br />
HCV Patients with advanced liver disease, thalassemics, those with HIV co-infection or those with kidney disease undergoing dialysis who have hepatitis C need daclatasvir in combination with sofosbuvir for effective treatment. They cannot tolerate interferon and/or ribavirin and treatment with sofosbuvir alone was not possible for them. Hence they were left with no treatment option when the manufacturer of daclatasvir, Bristol Myers Squibbs (BMS), was not willing to bring the drug to India or other developing countries.<br />
<br />
Sofosbuvir was registered in India in January 2015 and daclatasvir was registered this month. The combo is seen as a very potent cure with about 90% cure rate and for no other disease has such a short-time cure become available, that too in a generic version.<br />
<br />
According to the recommendations of a high level committee, waiver of clinical trials in India for approval of a new drug that has already been approved outside India can be considered only in cases of national emergency, extreme urgency, and epidemic and for orphan drugs for rare diseases and drugs indicated for conditions/diseases for which there is no therapy. This was hampering the waiver that millions of Hep C patients were petitioning for.<br />
<br />
However, the technical committee, after examining the case of sofosbuvir, said that it was the only drug which could be safely used in several categories of Hepatitis C patients. In the case of daclatasvir, the committee said that the drug in combination with other medicinal products became imperative to expedite the treatment of all types (genotypes) of Hepatitis C and hence recommended the waiver.<br />
<br />
&quot;We welcome the availability of a pan-genotypic directly acting anti-viral (DAA) combination in India, which is a big step towards interferon free treatment for chronic HCV patients, many of whom urgently need treatment as they have advanced liver disease,&quot; said Leena Menghaney, head of MSF's South Asia Access Campaign.<br />
<br />
</div>',
	'credit_writer' => 'The Times of India, 29 November, 2015, http://timesofindia.indiatimes.com/home/science/Hepatitis-C-cure-may-cost-as-low-as-Rs-67k/articleshow/49966218.cms',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'hepatitis-c-cure-may-cost-as-low-as-rs-67k-reema-nagarajan-4677900',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 4677900,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 29843
$metaTitle = 'LATEST NEWS UPDATES | Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan'
$metaKeywords = 'Access to Health,Access to Healthcare,generic medicines,Hepatitis C,Access to Medicines'
$metaDesc = '
-The Times of India

NEW DELHI: In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial...'
$disp = '<div align="justify">-The Times of India<br /><br /><em>NEW DELHI: </em>In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease.<br /><br />The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction of the branded versions, into the Indian market within weeks. Some patients facing a threat to life currently import these drugs at a huge cost.<br /><br />According to the World Health Organisation, about 12 million people are infected with Hepatitis C in India. India is now one of the few countries where generics are available for interferon-free treatment. Pegylated interferon is an old, expensive, injectable chemotherapy drug with serious side effects used to treat Hep C in combination with sofosbuvir and ribavirin.<br /><br />The interferon-free treatment, which costs over $90,000 in the US and over 50,000 euros in the EU will be available to Indian patients for about Rs 55,000 or about $1,000 or even less thanks to competition between generic manufacturers.<br /><br />Indian generics are expected to revolutionise Hep C treatment in the region and all across the world as they did in the case of HIV/AIDS. People from countries where treatment is being rationed by the governments, such as in Australia, many European countries, the US, and Canada, already come to India to get treated and this trend is only likely to continue.<br /><br />Several patient groups, including International Treatment Preparedness Coalition - South Asia, the Delhi Network of Positive People, thalassemic patients' groups and Medecins Sans Frontieres (MSF) or Doctors Without Borders have been petitioning the health ministry and the Drug Controller General of India (DCGI) seeking a clinical trial waiver for these drugs. Over a dozen patient groups and access-to-medicine activists from Indonesia, Thailand, Malaysia, Nepal and Vietnam too had sent similar appeals. &quot;The requirement for a local clinical trial in India will delay the introduction of the new HCV drug daclatasvir in the country, and also in other high-burden countries in the region,&quot; stated the appeals.<br /><br />HCV Patients with advanced liver disease, thalassemics, those with HIV co-infection or those with kidney disease undergoing dialysis who have hepatitis C need daclatasvir in combination with sofosbuvir for effective treatment. They cannot tolerate interferon and/or ribavirin and treatment with sofosbuvir alone was not possible for them. Hence they were left with no treatment option when the manufacturer of daclatasvir, Bristol Myers Squibbs (BMS), was not willing to bring the drug to India or other developing countries.<br /><br />Sofosbuvir was registered in India in January 2015 and daclatasvir was registered this month. The combo is seen as a very potent cure with about 90% cure rate and for no other disease has such a short-time cure become available, that too in a generic version.<br /><br />According to the recommendations of a high level committee, waiver of clinical trials in India for approval of a new drug that has already been approved outside India can be considered only in cases of national emergency, extreme urgency, and epidemic and for orphan drugs for rare diseases and drugs indicated for conditions/diseases for which there is no therapy. This was hampering the waiver that millions of Hep C patients were petitioning for.<br /><br />However, the technical committee, after examining the case of sofosbuvir, said that it was the only drug which could be safely used in several categories of Hepatitis C patients. In the case of daclatasvir, the committee said that the drug in combination with other medicinal products became imperative to expedite the treatment of all types (genotypes) of Hepatitis C and hence recommended the waiver.<br /><br />&quot;We welcome the availability of a pan-genotypic directly acting anti-viral (DAA) combination in India, which is a big step towards interferon free treatment for chronic HCV patients, many of whom urgently need treatment as they have advanced liver disease,&quot; said Leena Menghaney, head of MSF's South Asia Access Campaign.<br /><br /></div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Hepatitis C cure may cost as low as Rs 67k -Reema Nagarajan

-The Times of India NEW DELHI: In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease. The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction of the branded versions, into the Indian market within weeks. Some patients facing a threat to life currently import these drugs at a huge cost. According to the World Health Organisation, about 12 million people are infected with Hepatitis C in India. India is now one of the few countries where generics are available for interferon-free treatment. Pegylated interferon is an old, expensive, injectable chemotherapy drug with serious side effects used to treat Hep C in combination with sofosbuvir and ribavirin. The interferon-free treatment, which costs over $90,000 in the US and over 50,000 euros in the EU will be available to Indian patients for about Rs 55,000 or about $1,000 or even less thanks to competition between generic manufacturers. Indian generics are expected to revolutionise Hep C treatment in the region and all across the world as they did in the case of HIV/AIDS. People from countries where treatment is being rationed by the governments, such as in Australia, many European countries, the US, and Canada, already come to India to get treated and this trend is only likely to continue. Several patient groups, including International Treatment Preparedness Coalition - South Asia, the Delhi Network of Positive People, thalassemic patients' groups and Medecins Sans Frontieres (MSF) or Doctors Without Borders have been petitioning the health ministry and the Drug Controller General of India (DCGI) seeking a clinical trial waiver for these drugs. Over a dozen patient groups and access-to-medicine activists from Indonesia, Thailand, Malaysia, Nepal and Vietnam too had sent similar appeals. "The requirement for a local clinical trial in India will delay the introduction of the new HCV drug daclatasvir in the country, and also in other high-burden countries in the region," stated the appeals. HCV Patients with advanced liver disease, thalassemics, those with HIV co-infection or those with kidney disease undergoing dialysis who have hepatitis C need daclatasvir in combination with sofosbuvir for effective treatment. They cannot tolerate interferon and/or ribavirin and treatment with sofosbuvir alone was not possible for them. Hence they were left with no treatment option when the manufacturer of daclatasvir, Bristol Myers Squibbs (BMS), was not willing to bring the drug to India or other developing countries. Sofosbuvir was registered in India in January 2015 and daclatasvir was registered this month. The combo is seen as a very potent cure with about 90% cure rate and for no other disease has such a short-time cure become available, that too in a generic version. According to the recommendations of a high level committee, waiver of clinical trials in India for approval of a new drug that has already been approved outside India can be considered only in cases of national emergency, extreme urgency, and epidemic and for orphan drugs for rare diseases and drugs indicated for conditions/diseases for which there is no therapy. This was hampering the waiver that millions of Hep C patients were petitioning for. However, the technical committee, after examining the case of sofosbuvir, said that it was the only drug which could be safely used in several categories of Hepatitis C patients. In the case of daclatasvir, the committee said that the drug in combination with other medicinal products became imperative to expedite the treatment of all types (genotypes) of Hepatitis C and hence recommended the waiver. "We welcome the availability of a pan-genotypic directly acting anti-viral (DAA) combination in India, which is a big step towards interferon free treatment for chronic HCV patients, many of whom urgently need treatment as they have advanced liver disease," said Leena Menghaney, head of MSF's South Asia Access Campaign.